The BioNTech SE ADR BNTX slid 1.35% to $99.27 Wednesday, on what proved to be an all-around favorable trading session for the ...

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

BioNTech SE ADR closed $19.25 below its 52-week high ($119.78), which the company achieved on September 11th.

GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein ...

The recommendation comes just a day after the Food and Drug administration signed off on the updated vaccines from Pfizer-BioNTech and Moderna. The director of the Centers for Disease Control and ...

Analyst John Newman of Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), retaining the price target of ...

The newest, updated Covid-19 vaccines are now FDA-approved and available, including the mRNA ones from Pfizer-BioNTech and ...

J.P. Morgan analyst Jessica Fye maintained a Sell rating on BioNTech SE (BNTX – Research Report) today and set a price target of $91.00.

Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or ...

Tempus AI, Inc. (NASDAQ: TEM, "Tempus"), a technology company leading the adoption of AI to advance precision medicine and ...

A third COVID-19 vaccine will be available shortly as Novavax joins Pfizer/BioNTech and Moderna in targeting variants that ...